SMAD family member 4Genealiases: DPC4 · JIP · MADH4 · MYHRS
Q-omics provides the consensus-scored SMAD4 profile across patient tissues and cancer cell-line models. SMAD4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SMAD4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, SMAD4 RNA expression shows 21,912 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where SMAD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD4 survival associations across molecular data types. SMAD4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD4 RNA expression–survival associations across cancer types. High SMAD4 expression shows unfavorable associations in ACC, but favorable associations in KIRC, PAAD, GBM, THYM and PRAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SMAD4 RNA expression.
This table summarizes SMAD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SMAD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD4 shows lower tumor expression in THCA, COAD, READ, LUAD, BRCA and KICH. The THCA box plot shows higher SMAD4 RNA expression in normal versus tumor tissue (log2 FC = −0.734, t-test p < 0.001).
This table shows molecular features associated with SMAD4 in patient tissues and cancer cell lines. In patient samples, SMAD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
